Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Weekly Subcutaneous Pegzilarginase in Arginase 1 Deficiency
NCT05676853Phase 3
Key facts
- Status
- Terminated
- Start
- Apr 2023
- Primary completion
- Apr 2023
- Countries
- 1
- Sponsor
- Spyre Therapeutics, Inc.
- Modality
- PEGylated Peptides, Replacement Enzymes
- Drugs
- pegzilarginase
- Conditions
- arginase 1 deficiency (ARG1-D)
01
Overview
Phase 3, open-label, single-arm trial of pegzilarginase in arginase 1 deficiency (ARG1-D), sponsored by Spyre Therapeutics, Inc. Primary endpoint: Treatment emergent adverse events at Week 54. Started Apr 2023; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Pegzilarginase
Weekly subcutaneous dosing of pegzilarginase plus individualized disease management
03
Who it enrols
Patients with Arginase 1 Deficiency who have previously enrolled in pegzilarginase clinical studies.
04
Endpoints
Primary
Treatment emergent adverse events
Beyond the preview
Go deeper on NCT05676853.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676853.